Comparative Pharmacology
Head-to-head clinical analysis: LARIN 1 20 versus LO MINASTRIN FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARIN 1 20 versus LO MINASTRIN FE.
LARIN 1/20 vs LO MINASTRIN FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases cervical mucus viscosity, inhibiting sperm penetration; alters endometrial receptivity.
Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Inhibits ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, inhibiting sperm penetration; alters endometrial lining, reducing implantation likelihood.
One tablet (0.1 mg levonorgestrel/20 mcg ethinyl estradiol) orally once daily for 21 days followed by 7 placebo days.
1 tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol/ferrous fumarate 75 mg) orally once daily for 28 consecutive days.
None Documented
None Documented
Norethindrone: 7.6 hours (range 5-14); Ethinyl estradiol: 13.2 hours (range 8-20). Clinical context: Steady-state achieved within 5-10 days.
Norethindrone: 8-11 hours; ethinyl estradiol: 12-16 hours. Steady-state achieved after 5-7 days of dosing.
Approximately 60% renal (30% norethindrone, 30% ethinyl estradiol metabolites) and 40% fecal (biliary excretion of conjugates).
Renal: 40-50% as conjugated metabolites; fecal: 20-30% via biliary excretion; unchanged drug <1%.
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive